Atherosclerosis occurs in arterial regions with disturbed blood flow, where endothelial cells are exposed to stress, thus activating proatherogenic signals that promote endothelial dysfunction and reprogramming, among others. Researchers have identified heart development protein with EGF like domains 1 (HEG1) as a flow-sensitive gene in murine artery endothelial cells.
Acinetobacter baumannii, a gram-negative opportunistic bacteria causing nosocomial bloodstream, urinary tract and airway infections, poses a high disease burden worldwide, particularly in Sub-Saharan Africa. Moreover, A. baumannii is a multidrug resistance (MDR) critical priority pathogen that could contribute up to 10 million deaths annually by 2050. Therefore, novel antibiotic approaches to treat MDR A. baumannii constitute a critical medical need.
Voyager Therapeutics Inc. has entered into a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy (SMA).
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. has received FDA clearance of its IND application for a phase I trial in the U.S. of ABP-745, an anti-inflammatory oral small-molecule drug, for the treatment of acute gout.
The contribution of alternative RNA splicing in the progression of pancreatic ductal adenocarcinoma (PDAC) has not been deeply explored. In a recent study, the RNA-binding protein RNA binding fox-1 homolog 2 (RBFOX2) was investigated, since its role in modulating alternative splicing in PDAC is not well understood.
Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent model.
Recent studies have identified 70 oxygenized phosphatidylcholine (PC)-containing epoxy and hydroperoxide groups that are generated in the early phase of acetaminophen (APAP)-induced acute liver injury. In a new study, researchers from the University of Tokyo focused on arachidonate PC and assessed the role of liver-specific LPCAT3 (lysophospholipid acyltransferase 3) on APAP-induced acute liver injury in mice.
JAK1 signaling promotes skin inflammation and is a major therapeutic target for atopic dermatitis-related itching. But in a study appearing in the Jan. 4, 2024, print issue of Cell after earlier publication online, researchers at the Icahn School of Medicine at Mount Sinai, led by dermatologist Brian Kim, found that intrinsic JAK1 signaling in sensory neurons had an immunoprotective effect in the lung. The findings suggest a more precise and personalized approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
Kinoteck Therapeutics Co. Ltd. have prepared and tested new ribosomal protein S6 kinase alpha-3 (RSK-2; MAPKAPK-1b) inhibitors potentially useful for the treatment of cancer.
RSS
